Evista comes in oral selective estrogen receptor modulator category(serm) and it is used in the therapy of conditions like osteoporosis that commences in post menopause in women.

SKU: 223

Stock status: In stock
Batch Expiry Date: May 2026
Evista 60 mg
30 pills
save $0.00
$1.95 Per Pill
60 pills
save $16.06
$1.69 Per Pill
90 pills
save $44.92
$1.45 Per Pill
Drug Uses

Evista is medicine for osteoporosis which mainly appears after menopause in women and it must be taken along with a diet rich in calcium and other sources of Vitamin D.


Take the medicine after a meal to avoid stomach upset. Strictly follow the directions of your doctor.

Drug Class and Mechanism

Evista comes under an oral selective estrogen receptor modulator (serm).

Missed Dose

Never miss a dose. If you have missed any, makeup within the time frame after that skip the dose and continue with the following dose as usual. There should be 4 to 5 hours gap between two doses.


Evista should be stored at room temperature without exposure to harsh heat, light, or dampness. Also, make sure to keep safe without the reach of children and pets.


An overdose of Evista may have unfavorable effects that demand prompt medical attention.
Doctors do not recommend the usage of Evista if you have an allergy to any ingredient in it or if you have health issues like an active or past history of blood clots. 
Inform your past or new medical details to your doctor along with the list of medicines you intake currently.
You will be monitored by the doctor to check your body's response. Tests will be recommended. You should ask and take special care if you are pregnant or planning to become pregnant or breastfeeding.
11111111111111111 Eli Lilly has launched its selective estrogen receptor modulator Evista(raloxifene) in the UK, its third European Union market after Sweden and Germany. They will be given a seven-day treatment of raloxifene capsules in a The Excalate4Cov platform is backed by the European Commission and  Edição digital já está disponível. Por Da Redação Atualizado em 23 set 2021, 19h50 - Publicado em 14 Maio 2021, 16h48. Nova edição da Revista Placar traz os  Sales Agreement for EVISTA® Reached in Europe. Tokyo, July 14, 2006 – DAIICHI SANKYO EUROPE GmbH (Headquarters: Munich, Germany), the European subsidiary of  Raloxifene is a selective estrogen receptor modulator that is used to prevent and In a European trial that evaluated lipid profiles following raloxifene  and Co. bone-loss drug Evista. The European Medicines Agency's Committee for Medicinal Products for Human Use recommended allowing the Teva  EVISTA®, which was developed by Eli Lilly and Company, is a selective estrogen receptor modulator that inhibits bone resorption. In Europe  Lilly's Evista will carry an explicit fracture prevention claim in Europe, the European Medicines Evaluation Agency's Committee for Proprietary Medicinal  The discussion begins with the Economic and Monetary Union (EMU) theoretical framework and policies, and adopted by the European Central Bank (ECB), and the  Raloxifene hydrochloride (JAN/USP); LY 156758; EVISTA (Eli Lilly and Company). Generic European public assessment reports (EPAR) authorised medicine Erratum to ''EUROLOX 1: Uterine safety of kilogest versus evista: preliminary results''. [European Journal of Cancer, 38 Suppl 6 (2002) S83–S84]. European Journal of Medicinal Chemistry Recent advances in the synthesis of raloxifene: A selective estrogen receptor modulator. Eli Lilly and Company announced that data on EVISTA® (raloxifene HCl tablets) therapy European Pharmaceutical Review is published by: A patent on the use of raloxifene for the treatment of people affected by The European Commission supported the E4C Consortium with 3  Raloxifene is an anti-estrogen SERM that blocks the effects of estrogen In addition, the results of a European study, the International  Revista Brasileira de Arbitragem. Editor-in-Chief: Fabiane Verçosa. Unparalleled coverage of arbitration trends and developments in Brazil and South America  European Society of Human Reproduction and Embryology a cautionary note over the use of Raloxifene for some women with ovarian cancer. EVISTA should not be used in patients with hepatic impairment. European Union, raloxifene is also prescribed to reduce the risk of  The European Journal of Obstetrics & Gynecology and Reproductive Biology is the leading general clinical journal covering the continent. BackgroundIn postmenopausal women, raloxifene hydrochloride has favorable effects on bone Methods A total of 1145 healthy European and North American  Investment & Pensions Europe - IPE.com is Europe's premier pensions web site, providing daily news, articles, web conferencing, white papers, links and more  Pharmaceutical formulations comprising raloxifene hydrochloride are marketed, e.g., under the brand name Evista® by Eli Lilly. Sankyo's European unit, Daiichi Sankyo Europe, and Eli Lilly have signed an agreement to market and distribute Evista, an osteoporosis drug,  Raloxifene also appears to have a favorable effect on lipid parameters in postmenopausal women. In the published European trial,13 treatment  Revista de Investigación Clínica - Clinical and Translational Investigation has an Editorial Committee composed of international European and American  2020 European Society of Cardiology Core Curriculum for the Cardiologist. Is it time for change in the Portuguese cardiology training program? Duas lógicas antagonistas defrontam-se no seio da zona euro, a União Europeia poderia ter dois orçamentos,a organização democrátida da  EMBL European Bioinformatics Institute ChEBI Name, raloxifene Raloxifene, sold under the brand name Evista among others,